Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
PTC Therapeutics price target raised to $46 from $42 at RBC Capital » 08:56
06/23/22
06/23
08:56
06/23/22
08:56
PTCT

PTC Therapeutics

$36.05 /

+1.99 (+5.84%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams raised the firm's price target on PTC Therapeutics to $46 from $42 and keeps a Sector Perform rating on the shares. The analyst is updating his model following this week's phase 3 study 041 data, increasing the probability that Translarna remains on the E.U. market to 95% from 80% and adding 25% risk-adjusted U.S. sales estimates. Shares have not fully rebounded and there is some optionality for Translarna U.S. and other pipeline assets like the Huntington's program, though the pipeline risks and loss of exclusivities likely balance out potential for a more dramatic upside inflection, Abrahams tells investors in a research note.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$36.05 /

+1.99 (+5.84%)

PTCT PTC Therapeutics
$36.05 /

+1.99 (+5.84%)

06/21/22 Credit Suisse
Credit Suisse taking 'wait-and-see approach' on PTC's Translarna in U.S.
06/21/22 Cantor Fitzgerald
Cantor says PTC should be up 30% today on Translarna study update
06/21/22 RBC Capital
PTC data may bring 'small hope' for U.S. approval, says RBC Capital
04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
PTCT PTC Therapeutics
$36.05 /

+1.99 (+5.84%)

Tuesday
Recommendations
Credit Suisse taking 'wait-and-see approach' on PTC's Translarna in U.S. » 13:18
06/21/22
06/21
13:18
06/21/22
13:18
PTCT

PTC Therapeutics

$33.60 /

+5.205 (+18.33%)

After PTC Therapeutics…

After PTC Therapeutics released topline data from Study 041, the company's Phase 3 placebo-controlled trial of Translarna in nonsense mutation DMD patients that was run subsequent to Translarna's conditional approval in the EU in pursuit of full EU approval, Credit Suisse analyst Judah Frommer said the EU commercial opportunity is worth up to $7 within his unchanged $51 price target. The totality of today's data is "supportive of the status quo for EMA," but he continues to take "a wait-and-see approach" for Translarna in the U.S., which he views as a $4-$7 per share opportunity that remains outside of his model for now, said Frommer, who keeps a Neutral rating on PTC shares.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$33.60 /

+5.205 (+18.33%)

PTCT PTC Therapeutics
$33.60 /

+5.205 (+18.33%)

06/21/22 Cantor Fitzgerald
Cantor says PTC should be up 30% today on Translarna study update
06/21/22 RBC Capital
PTC data may bring 'small hope' for U.S. approval, says RBC Capital
04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
PTCT PTC Therapeutics
$33.60 /

+5.205 (+18.33%)

Recommendations
Cantor says PTC should be up 30% today on Translarna study update » 10:42
06/21/22
06/21
10:42
06/21/22
10:42
PTCT

PTC Therapeutics

$31.89 /

+3.495 (+12.31%)

After PTC Therapeutics…

After PTC Therapeutics announced and discussed top line data from Study 041 of Translarna in patients with nonsense mutation Duchenne muscular dystrophy, or DMD, Cantor Fitzgerald analyst Kristen Kluska said she thinks these data will "significantly alleviate any investor concerns" about Translarna's future commercialization in the EU and she now expects the company could start to receive more credit around other pipeline candidates given her view that anticipation of this data had created "a bit of an overhang on the stock." Kluska, who believes shares should be trading up 30% today on this news, keeps an Overweight rating and $63 price target on PTC Therapeutics shares. In morning trading, PTC shares have gained $3.32, or about 12%, to $31.73.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$31.89 /

+3.495 (+12.31%)

PTCT PTC Therapeutics
$31.89 /

+3.495 (+12.31%)

06/21/22 RBC Capital
PTC data may bring 'small hope' for U.S. approval, says RBC Capital
04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
PTCT PTC Therapeutics
$31.89 /

+3.495 (+12.31%)

Recommendations
PTC data may bring 'small hope' for U.S. approval, says RBC Capital » 10:28
06/21/22
06/21
10:28
06/21/22
10:28
PTCT

PTC Therapeutics

$32.59 /

+4.195 (+14.77%)

RBC Capital analyst Brian…

RBC Capital analyst Brian Abrahams says the totality of PTC Therapeutics' Translarna in Duchenne muscular dystrophy data, in particular the statistically significant six-minute walk test improvements in the intent-to-treat population that mirrors the population the drug is currently used in. This, along with the open-label STRIDE data, should "very likely be good enough" to keep the drug on and reimbursed in the European market, Abrahams tells investors in a research note. The analyst had always seen European withdrawal as unlikely, "barring a complete whiff" in Study 041.He says increasing his probability of European market maintenance to 100% from 80% would add $2 to his fair value calculation. However, for the U.S., there are "some important nuances that make it uncertain whether the drug could be approvable," Abrahams writes. The study did not quite hit statistical significance on its intent-to-treat population using ANCOVA, notes the analyst. However, he believes there are little expectations in PTC's valuation for potential U.S. approval of Translarna, and that there is" likely enough here - and perhaps more than expected" to raise at least some small hope FDA might consider the totality of the data in this high unmet need indication. Abrahams keeps a Sector Perform rating on PTC Therapeutics with a $42 price target.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$32.59 /

+4.195 (+14.77%)

PTCT PTC Therapeutics
$32.59 /

+4.195 (+14.77%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$32.59 /

+4.195 (+14.77%)

Hot Stocks
PTC Therapeutics rallies after Duchenne muscular dystrophy study results » 10:01
06/21/22
06/21
10:01
06/21/22
10:01
PTCT

PTC Therapeutics

$33.44 /

+5.04 (+17.75%)

PTC Therapeutics hosted a…

PTC Therapeutics hosted a conference call this morning to discuss the top-line results from the placebo-controlled trial of Study 041 for Translarna in Duchenne muscular dystrophy patients. The drug resulted in "significant benefit" across key endpoints in the intent-to-treat population, PTC said in a slide presentation. Translarna demonstrated the greatest effects in patients with baseline six-minute walk test of 300-400 meters in previous trials, according to the company. Shares of PTC Therapeutics are up 17% to $33.10 following the study results.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$33.44 /

+5.04 (+17.75%)

PTCT PTC Therapeutics
$33.44 /

+5.04 (+17.75%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$33.44 /

+5.04 (+17.75%)

Over a week ago
Hot Stocks
PTC Therapeutics reports 'encouraging' results from Phase 1B study of unesbulin » 08:03
06/03/22
06/03
08:03
06/03/22
08:03
PTCT

PTC Therapeutics

$27.17 /

-1.905 (-6.55%)

PTC Therapeutics…

PTC Therapeutics announced encouraging preliminary safety and efficacy results from its Phase 1B study of unesbulin in advanced leiomyosarcoma patients. The results demonstrated that treated patients achieved an 18.2% objective response rate and a 51.5% disease control rate. In addition, unesbulin was generally well tolerated. The results from the dose escalation study which evaluated unesbulin in combination with dacarbazine, will be presented on Saturday, June 4, during the Sarcoma Oral Abstract Session beginning at 1:15 p.m. CDT at the 2022 American Society of Clinical Oncology Annual Meeting in Chicago. Based on the preliminary data from the Phase 1B study, PTC has initiated the SUNRISE LMS study. SUNRISE LMS is an international, placebo-controlled, registration-directed study comparing the efficacy and safety of unesbulin and DTIC versus placebo and DTIC in patients with advanced LMS who have received greater than or equal to1 prior line of systemic therapy. The study is ongoing.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$27.17 /

-1.905 (-6.55%)

PTCT PTC Therapeutics
$27.17 /

-1.905 (-6.55%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$27.17 /

-1.905 (-6.55%)

Hot Stocks
PTC Therapeutics announces FDA approval for Evrysdi label extension » 05:22
05/31/22
05/31
05:22
05/31/22
05:22
PTCT

PTC Therapeutics

$30.32 /

-0.37 (-1.21%)

PTC Therapeutics…

PTC Therapeutics announced that the FDA has approved a label extension for Evrysdi to include infants under two months old with spinal muscular atrophy, or SMA.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$30.32 /

-0.37 (-1.21%)

PTCT PTC Therapeutics
$30.32 /

-0.37 (-1.21%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$30.32 /

-0.37 (-1.21%)

Over a month ago
Hot Stocks
PTC Therapeutics receives positive CHMP opinion for Upstaza » 08:09
05/20/22
05/20
08:09
05/20/22
08:09
PTCT

PTC Therapeutics

$32.50 /

+0.945 (+3.00%)

PTC Therapeutics…

PTC Therapeutics announced that Upstaza received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency. Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain. PTC expects the European Commission to ratify the marketing authorization for Upstaza under exceptional circumstances in approximately two months. The decision will be applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$32.50 /

+0.945 (+3.00%)

PTCT PTC Therapeutics
$32.50 /

+0.945 (+3.00%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$32.50 /

+0.945 (+3.00%)

Earnings
PTC Therapeutics sees FY22 revenue $700M-$750M, consensus $721.44M » 16:09
05/03/22
05/03
16:09
05/03/22
16:09
PTCT

PTC Therapeutics

$35.78 /

-0.28 (-0.78%)

Sees FY22 PTC revenues…

Sees FY22 PTC revenues for the DMD franchise $475M-$495M; GAAP R&D and SG&A expenses $915M-$965M; Non-GAAP R&D and SG&A expense $800M-$850M, excluding estimated non-cash, stock-based compensation expense of $115M.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$35.78 /

-0.28 (-0.78%)

PTCT PTC Therapeutics
$35.78 /

-0.28 (-0.78%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$35.78 /

-0.28 (-0.78%)

Earnings
PTC Therapeutics reports Q1 EPS ($1.78), consensus ($1.51) » 16:07
05/03/22
05/03
16:07
05/03/22
16:07
PTCT

PTC Therapeutics

$35.66 /

-0.4 (-1.11%)

Reports Q1 revenue…

Reports Q1 revenue $148.7M, consensus $147.06M. Cash, cash equivalents, and marketable securities were $587.8M on March 31, compared to $773.4M at December 31, 2021."We are continuing to build a robust pipeline of potential new therapeutics that at steady state we anticipate delivering a new product every 2-3 years," said Stuart W. Peltz, CEO. "With multiple ongoing registration-directed trials, we are well on the way to fulfill this vision."

ShowHide Related Items >><<
PTCT PTC Therapeutics
$35.66 /

-0.4 (-1.11%)

PTCT PTC Therapeutics
$35.66 /

-0.4 (-1.11%)

04/04/22 Cantor Fitzgerald
PTC Therapeutics assumed with an Overweight at Cantor Fitzgerald
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
10/18/21 BofA
PTC Therapeutics downgraded to Underperform from Neutral at BofA
08/31/21 UBS
PTC Therapeutics price target lowered to $45 from $55 at UBS
PTCT PTC Therapeutics
$35.66 /

-0.4 (-1.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.